CVS is in a strong uptrend, with the stock up 58.7% over the past year, significantly outperforming the S&P 500's 20.6% gain. The current price of $104.15 sits at 98.1% of its 52-week range ($58.50–$106.15), indicating the stock is near its highs and reflecting strong bullish momentum. This positioning suggests the market is pricing in continued positive catalysts, though it also raises the risk of short-term overextension. Short-term momentum is accelerating: the 1-month price change is +6.3% and the 3-month change is +31.3%, both outpacing the S&P 500's respective gains of 4.1% and 11.1%. This divergence from the broader market signals strong stock-specific catalysts, including the recent earnings beat and raised guidance. The relative strength over 1-month (2.18) and 3-month (20.18) confirms CVS is leading the market. The 52-week low of $58.50 provides a key support level, while the 52-week high of $106.15 is a near-term resistance. A breakout above $106.15 would signal further upside momentum, while a breakdown below $100 could indicate a pullback. CVS's beta of 0.60 is lower than the market, meaning it is 40% less volatile than the S&P 500, which may appeal to risk-averse investors but also implies less upside participation in strong markets.

Revenue growth is solid and accelerating: Q4 2025 revenue was $105.7 billion, up 8.2% year-over-year, compared to 6.3% growth in Q4 2024. The trailing twelve-month revenue reached $402.0 billion, driven by strong performance in Pharmacy Revenue ($61.6 billion) and Premiums ($34.0 billion) in the latest quarter. The growth trajectory is supported by the Aetna insurance segment and Oak Street Health's primary care expansion, though the retail front store revenue ($5.7 billion) remains a smaller contributor. Profitability has improved markedly: Q4 2025 net income was $2.94 billion, a sharp recovery from the Q3 2025 loss of $3.98 billion, which was driven by one-time charges. Gross margin was 12.8%, slightly below the prior year's 13.2%, but operating margin improved to 2.0% from 2.4% in Q4 2024. The net margin of 2.8% in Q4 2025 is above the trailing twelve-month net margin of 0.4%, indicating a strong rebound in profitability. The balance sheet is manageable: debt-to-equity is 1.24, and free cash flow for Q4 2025 was $2.61 billion, bringing TTM FCF to $7.81 billion. The current ratio of 0.84 suggests some liquidity pressure, but strong operating cash flow ($3.39 billion in Q4) provides ample coverage. ROE of 2.4% is low but improving from negative levels in Q3 2025, reflecting the earnings recovery.